Literature DB >> 36125533

A comprehensive insight into the anti-inflammatory properties of dapsone.

Mina Khalilzadeh1,2, Maryam Shayan1,2, Sina Jourian1,2, Mohammad Rahimi1,2, Mohammad Sheibani3,4, Ahmad Reza Dehpour5,6.   

Abstract

The 4,4'-diaminodiphenyl sulfone (DDS), also known as dapsone, is traditionally used as a potent anti-bacterial agent in clinical management of leprosy. For decades, dapsone has been among the first-line medications used in multidrug treatment of leprosy recommended by the World Health Organization (WHO). Shortly after dapsone's discovery as an antibiotic in 1937, the dual function of dapsone (anti-microbial and anti-inflammatory) was elucidated. Dapsone exerts its anti-bacterial effects by inhibiting dihydrofolic acid synthesis, leading to inhibition of bacterial growth, while its anti-inflammatory properties are triggered by inhibiting reactive oxygen species (ROS) production, reducing the effect of eosinophil peroxidase on mast cells and downregulating neutrophil-mediated inflammatory responses. Among the leading mechanisms associated with its anti-microbial/anti-protozoal effects, dapsone clearly has multiple antioxidant, anti-inflammatory, and anti-apoptotic functions. In this regard, it has been described in treating a wide variety of inflammatory and infectious skin conditions. Previous reports have explored different molecular targets for dapsone and provided insight into the anti-inflammatory mechanism of dapsone. This article reviews several basic, experimental, and clinical approaches on anti-inflammatory effect of dapsone.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Anti-inflammatory; Dapsone; Experimental models; Inflammation; Oxidative stress

Year:  2022        PMID: 36125533     DOI: 10.1007/s00210-022-02297-1

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.195


  113 in total

1.  Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone.

Authors:  P M Bozeman; D B Learn; E L Thomas
Journal:  Biochem Pharmacol       Date:  1992-08-04       Impact factor: 5.858

2.  Effect of dapsone on haemoglobin concentration in patients with leprosy.

Authors:  S R Byrd; R H Gelber
Journal:  Lepr Rev       Date:  1991-06       Impact factor: 0.537

3.  Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases.

Authors:  F Bouscarat; O Chosidow; C Picard-Dahan; V Sakiz; B Crickx; C Prost; J C Roujeau; J Revuz; S Belaich
Journal:  J Am Acad Dermatol       Date:  1996-04       Impact factor: 11.527

4.  Dapsone--other indications.

Authors:  V P Barranco
Journal:  Int J Dermatol       Date:  1982-11       Impact factor: 2.736

5.  Chemoprophylaxis in malaria.

Authors:  D Bell
Journal:  J Antimicrob Chemother       Date:  1980-01       Impact factor: 5.790

6.  The effect of dapsone in steroid-dependent asthma.

Authors:  B A Berlow; M I Liebhaber; Z Dyer; T M Spiegel
Journal:  J Allergy Clin Immunol       Date:  1991-03       Impact factor: 10.793

7.  Inhibition of the release of prostaglandins, leukotrienes and lysosomal acid hydrolases from macrophages by selective inhibitors of lecithin biosynthesis.

Authors:  R J Bonney; P D Wightman; M E Dahlgren; S J Sadowski; P Davies; N Jensen; T Lanza; J L Humes
Journal:  Biochem Pharmacol       Date:  1983-01-15       Impact factor: 5.858

8.  Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine.

Authors:  R A Ahmad; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

9.  Dapsone suppresses integrin-mediated neutrophil adherence function.

Authors:  S A Booth; C E Moody; M V Dahl; M J Herron; R D Nelson
Journal:  J Invest Dermatol       Date:  1992-02       Impact factor: 8.551

10.  A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-alpha production from activated mononuclear cells on cutaneous lupus erythematosus.

Authors:  M Abe; A Shimizu; Y Yokoyama; Y Takeuchi; O Ishikawa
Journal:  Clin Exp Dermatol       Date:  2008-08-16       Impact factor: 3.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.